Ge, X.; Yost, S.E.; Lee, J.S.; Frankel, P.H.; Ruel, C.; Cui, Y.; Murga, M.; Tang, A.; Martinez, N.; Chung, S.;
et al. Phase II Study Combining Pembrolizumab with Aromatase Inhibitor in Patients with Metastatic Hormone Receptor Positive Breast Cancer. Cancers 2022, 14, 4279.
https://doi.org/10.3390/cancers14174279
AMA Style
Ge X, Yost SE, Lee JS, Frankel PH, Ruel C, Cui Y, Murga M, Tang A, Martinez N, Chung S,
et al. Phase II Study Combining Pembrolizumab with Aromatase Inhibitor in Patients with Metastatic Hormone Receptor Positive Breast Cancer. Cancers. 2022; 14(17):4279.
https://doi.org/10.3390/cancers14174279
Chicago/Turabian Style
Ge, Xuan, Susan E. Yost, Jin Sun Lee, Paul H. Frankel, Christopher Ruel, Yujie Cui, Mireya Murga, Aileen Tang, Norma Martinez, Samuel Chung,
and et al. 2022. "Phase II Study Combining Pembrolizumab with Aromatase Inhibitor in Patients with Metastatic Hormone Receptor Positive Breast Cancer" Cancers 14, no. 17: 4279.
https://doi.org/10.3390/cancers14174279
APA Style
Ge, X., Yost, S. E., Lee, J. S., Frankel, P. H., Ruel, C., Cui, Y., Murga, M., Tang, A., Martinez, N., Chung, S., Yeon, C., Stewart, D., Li, D., Rajurkar, S., Somlo, G., Mortimer, J., Waisman, J., & Yuan, Y.
(2022). Phase II Study Combining Pembrolizumab with Aromatase Inhibitor in Patients with Metastatic Hormone Receptor Positive Breast Cancer. Cancers, 14(17), 4279.
https://doi.org/10.3390/cancers14174279
